MCID: CRY003
MIFTS: 54

Cryptosporidiosis

Categories: Gastrointestinal diseases, Immune diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Cryptosporidiosis

MalaCards integrated aliases for Cryptosporidiosis:

Name: Cryptosporidiosis 12 74 52 58 54 42 3 43 15 71 32
Cryptosporidial Gastroenteritis 12 71
Infection by Cryptosporidium 12
Intestinal Cryptosporidiosis 12

Characteristics:

Orphanet epidemiological data:

58
cryptosporidiosis
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-9/100000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare infectious diseases


Summaries for Cryptosporidiosis

MedlinePlus : 42 Cryptosporidiosis (crypto) is an illness caused by a parasite. The parasite lives in soil, food, and water. It may also be on surfaces that have been contaminated with feces (poop). You can become infected by swallowing the parasite, if it is in your food, drinking water, or water that you swim in. You can also get it by touching your mouth with contaminated hands. The most common symptom of crypto is watery diarrhea. Other symptoms include Dehydration Weight loss Stomach cramps or pain Fever Nausea Vomiting Contact your health care provider if you have watery diarrhea that lasts more than a few days. Most people with crypto get better without treatment within one to two weeks. But crypto can cause serious problems in people with weak immune systems, like those with HIV/AIDS. To reduce your risk of crypto, wash your hands often, only drink water that you know is safe, and wash or peel fresh fruits and vegetables before eating. Centers for Disease Control and Prevention

MalaCards based summary : Cryptosporidiosis, also known as cryptosporidial gastroenteritis, is related to gastroenteritis and toxoplasmosis, and has symptoms including fever and pruritus. An important gene associated with Cryptosporidiosis is CD40LG (CD40 Ligand), and among its related pathways/superpathways are CCR5 Pathway in Macrophages and Allograft rejection. The drugs Azithromycin and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include small intestine, lung and t cells, and related phenotypes are immunodeficiency and decreased proportion of cd4-positive helper t cells

Disease Ontology : 12 A coccidiosis that involves a parasitic protozoan infection of the intestine of humans and a wide range of animals caused by Cryptosporidium species, through contaminated water and food, The symptoms include watery diarrhea, dehydration, weight loss, abdominal pain, fever, nausea and vomiting. Cryptosporidium infections have also been found in other digestive tract organs, the lungs, and conjunctiva. Immunocompromised persons are at greater risk of developing the infection.

NIH Rare Diseases : 52 Cryptosporidiosis is an illness caused by the parasite, Cryptosporidium. The condition is most commonly associated with watery diarrhea. Other signs and symptoms may include dehydration, weight loss, stomach cramps, fever, nausea and/or vomiting. Cryptosporidiosis occurs when the parasite enters the body, often through contaminated food and water or because of poor handwashing hygiene. Although cryptosporidiosis can affect all people, young children, pregnant women and people with severely weakened immune systems (i.e. those with AIDS; cancer and transplant patients who are taking certain immunosuppressive drugs; and those with inherited diseases that affect the immune system ) are likely to develop a more serious illness. Medications such as nitazoxanide have been used to treat diarrhea in both adults and children. However, most people who have healthy immune systems will recover without treatment.

CDC : 3 Many species and genotypes of the apicomplexan protozoan Cryptosporidium can infect humans and have a wide range of host animals. Zoonotic species and genotypes of Cryptosporidium are those transmitted from animal hosts to humans, and non-zoonotic species and genotypes are host-adapted without evidence of transmission from animals to humans. Cryptosporidium parvum (formerly known as C. parvum genotype II) and C. hominis (formerly known as C. parvum genotype I) are the leading causes of human cryptosporidiosis. C. meleagridis, C. felis, C. canis, C. ubiquitum, C. cuniculus, C. viatorum, Chipmunk genotype I, Cryptosporidium mink genotype, and C. muris can also infect humans.

Wikipedia : 74 Cryptosporidiosis, sometimes informally called crypto, is a parasitic disease caused by Cryptosporidium,... more...

Related Diseases for Cryptosporidiosis

Diseases related to Cryptosporidiosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 418)
# Related Disease Score Top Affiliating Genes
1 gastroenteritis 31.3 CSF3 CCL11 CAT
2 toxoplasmosis 31.1 DHFR CD79A CD40LG
3 immune deficiency disease 30.8 MBL2 IL1A CXCL10 CD79A CD40LG CD4
4 dysentery 30.8 IL1A CD40LG CD4
5 amebiasis 30.7 CD79A CD40LG CD4
6 bronchiolitis 30.6 IL1A CXCL10 CD40LG CCL11
7 cyclosporiasis 30.6 TPI1 CD4 ALLC
8 irritable bowel syndrome 30.3 VIP TAC1 SST
9 proteasome-associated autoinflammatory syndrome 1 30.3 IL1A CXCL10 CCL11
10 strongyloidiasis 30.3 CD79A CD4 CCL11
11 giardiasis 30.2 TPI1 CD8A CD79A CD40LG CD4 CACNA1B
12 respiratory failure 30.2 TAC1 CXCL10 CD40LG CD4 CCL11 CAT
13 pyelonephritis 30.2 MBL2 IL1A CXCL10 CSF3
14 constipation 30.2 VIP TAC1 SST CAT
15 leprosy 3 30.2 CXCL10 CD8A CD40LG CD4
16 chlamydia 30.1 MBL2 IL1A CD79A CD40LG
17 duodenitis 30.1 CD8A CD40LG CD4
18 bronchopneumonia 30.1 CD8A CD40LG CD4
19 chickenpox 30.1 CD8A CD40LG CD4
20 poliomyelitis 30.1 CD8A CD40LG CD4
21 bronchitis 30.1 VIP TAC1 CXCL10 CD40LG CCL11 CAT
22 pneumocystosis 30.0 DHFR CSF3 CD8A CD40LG CD4
23 oral candidiasis 30.0 IL1A CD8A CD4
24 listeriosis 30.0 MBL2 CD8A CD4
25 human immunodeficiency virus infectious disease 30.0 MBL2 CD8A CD79A CD4
26 cd40 ligand deficiency 29.9 CSF3 CD8A CD40LG CD4
27 exanthem 29.9 CSF3 CD8A CD40LG CD4
28 parasitic helminthiasis infectious disease 29.9 CD8A CD40LG CD4 CCL11
29 herpes zoster 29.9 DHFR CD8A CD40LG CD4
30 celiac disease 1 29.8 CD8A CD79A CD40LG CD4
31 thrombocytopenia 29.7 MBL2 IL1A CXCL10 CSF3 CD79A CD40LG
32 pancytopenia 29.7 DHFR CSF3 CD8A CD40LG CD4
33 immunoglobulin alpha deficiency 29.6 MBL2 CD8A CD79A CD40LG CD4
34 bacterial infectious disease 29.4 MBL2 IL1A CSF3 CD8A CD40LG CD4
35 coccidiosis 29.4 HSPA4 DHFR CEMP1 CD8A CD40LG CD4
36 leukemia, acute lymphoblastic 29.3 DHFR CSF3 CD8A CD40LG CD4
37 parasitic protozoa infectious disease 29.3 TPI1 HSPA4 DHFR CXCL10 CD8A CD40LG
38 myeloma, multiple 29.2 HSPA4 CSF3 CD8A CD79A CD40LG CD4
39 inflammatory bowel disease 28.7 VIP TAC1 IL1A HSPA4 CXCL10 CD8A
40 malaria 28.1 TPI1 MBL2 IL1A HSPA4 DHFR CXCL10
41 cryptorchidism, unilateral or bilateral 11.3
42 diarrhea 11.1
43 acquired immunodeficiency syndrome 10.8
44 human immunodeficiency virus type 1 10.7
45 hemorrhagic fever-renal syndrome 10.6 CD79A CD40LG
46 c1q nephropathy 10.6 CD79A CD40LG
47 congenital rubella 10.6 CD40LG CAT
48 hilar lung carcinoma 10.6 CD79A CD40LG
49 lung hilum cancer 10.6 CD79A CD40LG
50 thymus small cell carcinoma 10.6 CSF3 CAT

Graphical network of the top 20 diseases related to Cryptosporidiosis:



Diseases related to Cryptosporidiosis

Symptoms & Phenotypes for Cryptosporidiosis

Human phenotypes related to Cryptosporidiosis:

58 31 (show all 30)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 immunodeficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002721
2 decreased proportion of cd4-positive helper t cells 31 frequent (33%) HP:0005407
3 failure to thrive 58 31 occasional (7.5%) Occasional (29-5%) HP:0001508
4 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
5 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
6 growth delay 58 31 occasional (7.5%) Occasional (29-5%) HP:0001510
7 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
8 chronic diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002028
9 intermittent diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002254
10 low-grade fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0011134
11 nausea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002018
12 abdominal colic 58 31 occasional (7.5%) Occasional (29-5%) HP:0011848
13 dehydration 58 31 very rare (1%) Very rare (<4-1%) HP:0001944
14 dysphagia 58 31 very rare (1%) Very rare (<4-1%) HP:0002015
15 cough 58 31 very rare (1%) Very rare (<4-1%) HP:0012735
16 hoarse voice 58 31 very rare (1%) Very rare (<4-1%) HP:0001609
17 respiratory failure 58 31 very rare (1%) Very rare (<4-1%) HP:0002878
18 respiratory distress 58 31 very rare (1%) Very rare (<4-1%) HP:0002098
19 hypoxemia 58 31 very rare (1%) Very rare (<4-1%) HP:0012418
20 respiratory tract infection 58 31 very rare (1%) Very rare (<4-1%) HP:0011947
21 pancreatitis 58 31 very rare (1%) Very rare (<4-1%) HP:0001733
22 abnormal esophagus morphology 58 31 very rare (1%) Very rare (<4-1%) HP:0002031
23 wheezing 58 31 very rare (1%) Very rare (<4-1%) HP:0030828
24 gastrointestinal obstruction 58 31 very rare (1%) Very rare (<4-1%) HP:0004796
25 cholangitis 58 31 very rare (1%) Very rare (<4-1%) HP:0030151
26 abdominal pain 58 Occasional (29-5%)
27 biliary tract abnormality 58 Very rare (<4-1%)
28 diarrhea 58 Frequent (79-30%)
29 decreased proportion of cd4-positive t cells 58 Frequent (79-30%)
30 abnormal t cell count 58 Frequent (79-30%)

UMLS symptoms related to Cryptosporidiosis:


fever, pruritus

MGI Mouse Phenotypes related to Cryptosporidiosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 CCL11 CD4 CD40LG CD79A CD8A CSF3
2 immune system MP:0005387 9.44 CCL11 CD4 CD40LG CD79A CD8A CSF3

Drugs & Therapeutics for Cryptosporidiosis

Drugs for Cryptosporidiosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 41)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 3 83905-01-5 447043 55185
2
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
3
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
4
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
5
Rifabutin Approved, Investigational Phase 3 72559-06-9 6323490 46783538
6
Peginterferon alfa-2a Approved, Investigational Phase 2, Phase 3 198153-51-4 5360545
7
Ribavirin Approved Phase 2, Phase 3 36791-04-5 37542
8
Nitazoxanide Approved, Investigational, Vet_approved Phase 3 55981-09-4 41684
9 Anti-Bacterial Agents Phase 3
10 Cytochrome P-450 Enzyme Inhibitors Phase 3
11 Hormone Antagonists Phase 3
12 Hormones Phase 3
13 Antitubercular Agents Phase 3
14 Antifungal Agents Phase 3
15 Antibiotics, Antitubercular Phase 3
16 Liver Extracts Phase 2, Phase 3
17 Anti-Infective Agents Phase 3
18 Antiparasitic Agents Phase 3
19 Antiprotozoal Agents Phase 3
20
Paromomycin Approved, Investigational Phase 1, Phase 2 7542-37-2, 1263-89-4 165580
21
Clofazimine Approved, Investigational Phase 2 2030-63-9 2794
22 Anti-Inflammatory Agents Phase 2
23 Interleukin-12 Phase 1, Phase 2
24
Loperamide Approved Phase 1 53179-11-6 3955
25
Spiramycin Approved Phase 1 24916-50-5
26 Immunoglobulins Phase 1
27 Antibodies Phase 1
28 Immunoglobulins, Intravenous Phase 1
29 Whey Protein Phase 1
30 Antidiarrheals Phase 1
31 Vaccines Phase 1
32
Iodine Approved, Investigational 7553-56-2 807
33
Diclazuril Investigational, Vet_approved 101831-37-2
34 Rho(D) Immune Globulin
35 gamma-Globulins
36 cadexomer iodine
37 Acidophilus
38 Cola
39 Immunologic Factors
40 Angiogenesis Inhibitors
41 Adjuvants, Immunologic

Interventional clinical trials:

(show all 31)
# Name Status NCT ID Phase Drugs
1 A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients Completed NCT00002122 Phase 3 Azithromycin;Rifabutin;Fluconazole
2 Impact of Nitazoxanide on Virologic Responses in Chronic HCV Infected Patients With Genotype 4: A Placebo-controlled Randomized Trial Completed NCT01197157 Phase 2, Phase 3 Placebo;Nitazoxanide
3 Open Label, Multi-Center Evaluation of Nitazoxanide for the Treatment of Cryptosporidiosis in Subjects With AIDS in the United States Terminated NCT00004986 Phase 3 Nitazoxanide
4 A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 Completed NCT00000771 Phase 2 Paromomycin sulfate
5 A Phase II/III Placebo-Controlled Study of Nitazoxanide (NTZ) For Persons With AIDS and Cryptosporidiosis Completed NCT00001081 Phase 2 Nitazoxanide
6 A Phase I/II Open Label Study of Nitazoxanide (NTZ) for the Treatment of Cryptosporidium Parvum in HIV Infected Infants, Children, and Adolescents Completed NCT00055107 Phase 1, Phase 2 Nitazoxanide
7 Fecal Microbiota Transplantation in Refractory Clostridium Difficile Colitis Recruiting NCT02127398 Phase 2
8 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis Terminated NCT03341767 Phase 2 Clofazimine;Placebo
9 A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic Cryptosporidiosis in AIDS Terminated NCT00057486 Phase 1, Phase 2 IL-12
10 A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients Completed NCT00002248 Phase 1 Cryptosporidium Immune Whey Protein Concentrate (Bovine)
11 Blinded, Placebo-Controlled, Single-Dose Pharmacokinetics and Dose Escalation, Efficacy, and Safety Study of Letrazuril for AIDS-Related Cryptosporidial Diarrhea Completed NCT00001018 Phase 1 Letrazuril
12 Single-Blind Efficacy Evaluation of Intravenous Spiramycin in Subjects With AIDS-Related Cryptosporidial Diarrhea Completed NCT00000980 Phase 1 Spiramycin
13 Phase I/II Open Label Evaluation of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients Completed NCT00002444 Phase 1 Nitazoxanide
14 Open-Label Compassionate Use of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients Unknown status NCT00002158 Nitazoxanide
15 Efficacy of Cow's Milk Immune Globulin in the Treatment of Chronic Intestinal Cryptosporidiosis in Patients With AIDS Completed NCT00002264 Cryptosporidium Immune Whey Protein Concentrate (Bovine)
16 Prevalence and Clinical Presentation of Respiratory Cryptosporidiosis Among Children With Diarrhea in Mulago Hospital, Uganda Completed NCT00507871
17 Oral/Intravenous Azithromycin in the Treatment of Cryptosporidiosis in Patients Whose Disease Has Not Been Controlled by Conventional Therapy Completed NCT00002328 Azithromycin
18 Azithromycin in the Treatment of Cryptosporidiosis in Patients With Acquired Immune Deficiency Syndrome (AIDS): A Randomized, Multi-Center, Placebo-Controlled, Double-Blind Study Completed NCT00002082 Azithromycin
19 Open-Label "Compassionate" Use Study of Spiramycin for the Treatment of Diarrhea Due to Chronic Cryptosporidiosis in Immunocompromised Patients Completed NCT00002062 Spiramycin
20 28 Day Protocol for the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433) Completed NCT00002278 Diclazuril
21 Protocol For the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433) Completed NCT00002027 Diclazuril
22 Pilot Intervention Trial of Ceramic Water Filters to Reduce the Burden of Cryptosporidium in Household Drinking Water in Rural Kenya. Completed NCT01695304
23 Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events Completed NCT01699841
24 Diagnostics of Intestinal Parasitosis in Inhabitants of Kuyavian-Pomeranian Province in Poland Completed NCT03490435
25 Field Studies of Human Immunity to Amebiasis in Bangladesh: A Prospective Study of Children Ages 0-17 Years Completed NCT02734264
26 Development of an Effective Treatment of Cryptosporidiosis in Bangladeshi Children Recruiting NCT04103216
27 Field Studies of Cryptosporidiosis and Enteropathogens in Bangladesh Active, not recruiting NCT02764918
28 Role of the Protozoa Cryptosporidium in the Development of Colorectal Cancer in Humans Not yet recruiting NCT04332705
29 Parasitic Causes of Secretory Diarrhea in Children and Chronically Ill Adult. Not yet recruiting NCT03166670
30 A Pilot, Proof-of-Concept, Dose-Escalating Trial of Recombinant Human Interleukin-12 (rhIL-12) Versus Placebo Along With Paromomycin and Azithromycin for Chronic Cryptosporidiosis in AIDS Terminated NCT00001128 Interleukin-12;Paromomycin sulfate;Azithromycin
31 Study of Patients With Parasitic Infections of the Gastrointestinal Tract Terminated NCT00001162

Search NIH Clinical Center for Cryptosporidiosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


nitazoxanide

Cochrane evidence based reviews: cryptosporidiosis

Genetic Tests for Cryptosporidiosis

Anatomical Context for Cryptosporidiosis

MalaCards organs/tissues related to Cryptosporidiosis:

40
Small Intestine, Lung, T Cells, Testes, Liver, Breast, Colon

Publications for Cryptosporidiosis

Articles related to Cryptosporidiosis:

(show top 50) (show all 3397)
# Title Authors PMID Year
1
Cryptosporidium spp. in groundwater supplies intended for human consumption - A descriptive review of global prevalence, risk factors and knowledge gaps. 61 42
32247994 2020
2
A retrospective epidemiological analysis of human Cryptosporidium infection in China during the past three decades (1987-2018). 61 42
32226011 2020
3
Viral, bacterial, and protozoan pathogens and fecal markers in wells supplying groundwater to public water systems in Minnesota, USA. 42
32325219 2020
4
Association of mannose-binding lectin deficiency with cryptosporidiosis. 61 54
16804842 2006
5
Serum mannose-binding lectin deficiency is associated with cryptosporidiosis in young Haitian children. 54 61
16804841 2006
6
Targeting DHFR in parasitic protozoa. 61 54
15718161 2005
7
Mannose-binding lectin is a component of innate mucosal defense against Cryptosporidium parvum in AIDS. 54 61
11054381 2000
8
Potential antifolate resistance determinants and genotypic variation in the bifunctional dihydrofolate reductase-thymidylate synthase gene from human and bovine isolates of Cryptosporidium parvum. 61 54
8855552 1996
9
Cryptosporidium and Giardia infections in dairy calves in southern Ethiopia. 61
32490221 2020
10
Associations of five food- and water-borne diseases with ecological zone, land use and aquifer type in a changing climate. 61
32570317 2020
11
Species and genotypes causing human cryptosporidiosis in New Zealand. 61
32494897 2020
12
Bayesian risk assessment model of human cryptosporidiosis cases following consumption of raw Eastern oysters (Crassostrea virginica) contaminated with Cryptosporidium oocysts in the Hillsborough River system in Prince Edward Island, Canada. 61
32258447 2020
13
Cryptosporidium species and cryptosporidiosis in Japan: a literature review and insights into the role played by animals in its transmission. 61
32536636 2020
14
Prevalence of Cryptosporidium Infection in the Global Population: A Systematic Review and Meta-analysis. 61
32514837 2020
15
Supply and demand-heme synthesis, salvage and utilization by Apicomplexa. 61
32530125 2020
16
Preventing and controlling Cryptosporidium spp. in aquatic facilities: environmental health practitioners' experiences in Victoria, Australia. 61
32459385 2020
17
Crossing the Vacuolar Rubicon: Structural Insights into Effector Protein Trafficking in Apicomplexan Parasites. 61
32521667 2020
18
Investigation of Cryptosporidium spp. Antigen By ELISA in Stool Specimens Sent to Our Laboratory between 2010 and 2018. 61
32482037 2020
19
Assessment of health risks from recreational exposure to Giardia and Cryptosporidium in coastal bathing waters. 61
32333348 2020
20
Enteric parasitic infections in children and dogs in resource-poor communities in northeastern Brazil: Identifying priority prevention and control areas. 61
32516309 2020
21
Plasma histidine concentrations as a specific biomarker for intestinal mucosal damage in calves with cryptosporidiosis. 61
32531563 2020
22
Novel drug targets for treatment of cryptosporidiosis. 61
32552166 2020
23
Cryptosporidium parvum Elongation Factor 1α Participates in the Formation of Base Structure at the Infection Site During Invasion. 61
31872225 2020
24
Emerging Infectious Diseases of Chelonians: An Update. 61
32327035 2020
25
Cryptosporidium spp surveillance and epidemiology in Ireland: a longitudinal cohort study employing duplex real-time PCR based speciation of clinical cases. 61
32409597 2020
26
Effect of Ginsenoside-Rh2 and Curcurbitacin-B on Cryptosporidium parvum in vitro. 61
32165146 2020
27
The global prevalence of Cryptosporidium infection in dogs: A systematic review and meta-analysis. 61
32278149 2020
28
Cryptosporidium parvum cyclic GMP-dependent protein kinase (PKG): An essential mediator of merozoite egress. 61
32348840 2020
29
Co-infection risk assessment of Giardia and Cryptosporidium with HIV considering synergistic effects and age sensitivity using disability-adjusted life years. 61
32220670 2020
30
Long-term production effects of clinical cryptosporidiosis in neonatal calves. 61
32277986 2020
31
The red fox (Vulpes vulpes) as a potential natural reservoir of human cryptosporidiosis by Cryptosporidium hominis in Northwest Spain. 61
32302466 2020
32
Cellular Identification and In Silico Characterization of Protein Phosphatase 2C (PP2C) of Cryptosporidium parvum. 61
32347536 2020
33
Molecular study and genotyping of Cryptosporidium baileyi and Cryptosporidium parvum from free-range and commercial broiler chickens in Guilan province, Iran. 61
31951878 2020
34
Clofazimine for treatment of cryptosporidiosis in HIV-infected adults (CRYPTOFAZ): an experimental medicine, randomized, double-blind, placebo-controlled phase 2a trial. 61
32277809 2020
35
A review of outbreaks of cryptosporidiosis due to unpasteurized milk. 61
32297163 2020
36
Genotyping and Subtyping Cryptosporidium To Identify Risk Factors and Transmission Patterns - Nebraska, 2015-2017. 61
32214081 2020
37
Importance of colostrum IgG antibodies level for prevention of infection with Cryptosporidium parvum in neonatal dairy calves. 61
32066023 2020
38
Cryptosporidium parvum gp40/15 Is Associated with the Parasitophorous Vacuole Membrane and Is a Potential Vaccine Target. 61
32143441 2020
39
From mice to men: Three cases of human infection with Cryptosporidium ditrichi. 61
31751756 2020
40
Detection of Cryptosporidium parvum in a Red-Eared Slider Turtle (Trachemys scripta elegans), a Noted Invasive Alien Species, Captured in a Rural Aquatic Ecosystem in Eastern Poland. 61
32141020 2020
41
Defining Stage-Specific Activity of Potent New Inhibitors of Cryptosporidium parvum Growth In Vitro. 61
32127445 2020
42
Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review. 61
32228484 2020
43
Zoonotic implications of camel diseases in Iran. 61
32160657 2020
44
Epidemiology of Cryptosporidiosis, New York City, New York, USA, 1995-20181. 61
32096465 2020
45
Clustering of cryptosporidiosis in Queensland, Australia, is not defined temporally or by spatial diversity. 61
32126239 2020
46
Transmission of Cryptosporidium spp. among human and animal local contact networks in sub-Saharan Africa: a multi-country study. 61
32150243 2020
47
The Silent Reservoir of Cryptosporidiosis. 61
32150616 2020
48
A One Health Approach to Tackle Cryptosporidiosis. 61
31983609 2020
49
Association between Cryptosporidium infection and cancer: A systematic review and meta-analysis. 61
31472267 2020
50
Correlates of pathological lesions associated with respiratory cryptosporidiosis prevalence in shot red grouse Lagopus lagopus scotica from moors in northern England. 61
31545656 2020

Variations for Cryptosporidiosis

Expression for Cryptosporidiosis

Search GEO for disease gene expression data for Cryptosporidiosis.

Pathways for Cryptosporidiosis

Pathways related to Cryptosporidiosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.59 HSPA4 CXCL10 CD4 CCL11 CACNA1B
2
Show member pathways
12.48 IL1A HSPA4 CD8A CD40LG CD4 CCL11
3 11.69 CSF3 CD8A CD79A CD4
4 11.25 IL1A CSF3 CD8A CD4
5 11.23 IL1A CXCL10 CSF3
6 10.79 IL1A CSF3 CD4
7 10.71 IL1A CXCL10 CSF3 CD40LG CCL11
8 10.5 CD8A CD79A CD40LG CD4

GO Terms for Cryptosporidiosis

Cellular components related to Cryptosporidiosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 VIP TAC1 SST MBL2 IL1A CXCL10
2 external side of plasma membrane GO:0009897 9.55 CXCL10 CD8A CD79A CD40LG CD4
3 extracellular space GO:0005615 9.32 TPI1 TAC1 SST MBL2 IL1A CXCL10

Biological processes related to Cryptosporidiosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.65 TAC1 IL1A CXCL10 CD40LG CCL11
2 cell surface receptor signaling pathway GO:0007166 9.55 SST CXCL10 CD8A CD79A CD4
3 cytokine-mediated signaling pathway GO:0019221 9.35 IL1A CXCL10 CSF3 CD4 CCL11
4 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.32 IL1A CD4
5 immune response GO:0006955 9.17 IL1A CXCL10 CSF3 CD8A CD40LG CD4

Molecular functions related to Cryptosporidiosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 IL1A CXCL10 CSF3 CD40LG CCL11

Sources for Cryptosporidiosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....